Vertex Pharma (VRTX) November 11 weekly 475 straddle priced into quarter results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Vertex (VRTX) PT Raised to $451 at RBC Capital
November 5, 2024 7:00 AM ESTRBC Capital analyst Brian Abrahams raised the price target on Vertex (NASDAQ: VRTX) to $451.00 (from $437.00) while maintaining a Sector Perform rating.
The analyst comments "CF beat and raise shows the continued health of the company's core franchise and is likely to perpetuate... More
